November 02, 2025

Get In Touch

Cough Syrup Deaths Case: Madhya Pradesh HC defers bail plea of paediatrician

Jabalpur:The Madhya Pradesh High Court on Thursday postponed the hearing of the bail plea of a paediatrician accused in connection withthe tragic deaths of24 children, allegedly caused by consumption of a now-banned toxiccough syrupin Chhindwara and Betul districts, due to lack of time. The accused physician from Chhindwara, Dr Praveen Soni, who prescribed the contaminatedcough syrup'Coldrif' to most of the ailing kids, has been arrested for alleged negligence in connection with the child deaths. Soni's bail plea was listed before a single bench of Justice Pramod Kumar Agrawal, but it could not be taken up for hearing due to a lack of time, his counsel Pawan Shukla informed, reports PTI. Also Read:MP CM Yadav to visit Chhindwara amid cough syrup crisis It is likely to be heard on Friday, Shukla told PTI. had earlier reported that, noting that substantial material indicates a serious offence, the Chhindwara Court has rejected the bail application of the arrested paediatrician, who prescribed Coldrif cough syrup to children, which is allegedly linked to their deaths due to kidney failure. Considering the facts, circumstances, and seriousness of the offence, Additional Sessions Judge Gautam Kumar Gujre observed, "On perusal of the available evidence, the court noted that substantial material indicates a serious offence. According to the FIR and supporting documents, other persons, including distributors and company representatives, were aware that the medicine Coldrif—which could cause a child’s death—was being manufactured and sold, yet it was still distributed and prescribed. As per officials, 22 children in Chhindwara and two in Betul died after consuming the Coldrif cough syrup manufactured by a private pharmaceutical firm whose owner was arrested from Tamil Nadu last week. Most of the deceased children, under the age of five, had been prescribed the syrup by Dr Soni. The children died due to suspected kidney failure following the consumption of the adulterated cough syrup. Madhya Pradesh authorities revealed that one sample of Coldrif had 48.6 per cent of diethylene glycol, a toxic substance found in industrial solvents, far exceeding the 0.1% permissible limit. Following the deaths, the Parasia police in Chhindwara district registered a case against the syrup's manufacturer, Sresan Pharma, its owner, G Ranganathan, Soni, and others under relevant sections of the BNS. Dr Soni approached the HC after the district court rejected his bail plea, which cited the serious nature of the case. He argued that police arrested him without obtaining prior permission from the medical board, a necessary requirement for action against a registered doctor. The physician maintained he had prescribed the syrup in good faith and pointed out he was neither involved in the medicine's production nor its sale. The doctor contended that the licence to manufacture and market the cough syrup had been issued to the company by competent government authorities. Also Read:Toxic syrup deaths case: 8,500 MP doctors protest against paediatrician's arrest

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!